A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated‐interferon alpha

Publisher Website
Google Scholar
Abstract
Hepatitis B surface antigen (HBsAg) clearance represents a clinical cure, although the clearance rate is extremely low. The aim of this study was to evaluate the feasibility and safety profiles of pegylated-interferon α-2a (PEG-IFNα-2a) as a therapeutic option for inactive HBsAg carriers. There were 144 inactive HBsAg carriers enrolled and divided into a therapeutic group (102 subjects) and a control group (42 subjects). PEG-IFNα-2a and PEG-IFNα-2a combined with adefovir dipivoxil were used for treatment group subjects with hepatitis B virus DNA Conclusion: High rates of HBsAg clearance and seroconversion could be achieved by PEG-IFNα-2a-based treatments and the treatments were relatively safe for inactive HBsAg carriers. (Hepatology 2017;66:1058-1066).
Funding Information
  • Capital Health Research and Development Projects (2011-2018-08, 2016-1-2183)
  • Capital Characteristic Clinical Application Research and Extension of Achievements (Z151100004015181, Z161100000516018)
  • Beijing Municipal Administration of Hospitals' Youth Program (QML20161701)
  • Twelfth Five-Year Major Science and Technology Projects (2013ZX1000 2002-006)
  • Fengtai District Health System Science Research Project (2016-57)
  • Beijing Youan Hospital Hepatic Disease & HIV Fund (YNKT20150205, 20160021)